These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 37453440)

  • 1. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
    Kirsebom FCM; Andrews N; Stowe J; Ramsay M; Lopez Bernal J
    Lancet Infect Dis; 2023 Nov; 23(11):1235-1243. PubMed ID: 37453440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England.
    Kirsebom FCM; Andrews N; Stowe J; Dabrera G; Ramsay M; Lopez Bernal J
    EClinicalMedicine; 2024 May; 71():102587. PubMed ID: 38618208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022.
    Chatzilena A; Hyams C; Challen R; Marlow R; King J; Adegbite D; Kinney J; Clout M; Maskell N; Oliver J; Finn A; Danon L;
    Euro Surveill; 2023 Nov; 28(48):. PubMed ID: 38037728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
    Mateo-Urdiales A; Sacco C; Fotakis EA; Del Manso M; Bella A; Riccardo F; Bressi M; Rota MC; Petrone D; Siddu A; Fedele G; Stefanelli P; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M
    Lancet Infect Dis; 2023 Dec; 23(12):1349-1359. PubMed ID: 37478877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    Kirsebom FCM; Stowe J; Lopez Bernal J; Allen A; Andrews N
    J Infect; 2024 Jul; 89(1):106177. PubMed ID: 38719110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
    Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.
    Sane Schepisi M
    Epidemiol Prev; 2023; 47(6):331-343. PubMed ID: 38314543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
    Surie D; DeCuir J; Zhu Y; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Ali H; Taghizadeh L; Gong MN; Mohamed A; Johnson NJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Columbus C; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Hart KW; Swan SA; Lewis NM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1625-1630. PubMed ID: 36580424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
    Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 71(53):1637-1646. PubMed ID: 36921274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
    Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1616-1624. PubMed ID: 36580430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
    Agrawal U; Bedston S; McCowan C; Oke J; Patterson L; Robertson C; Akbari A; Azcoaga-Lorenzo A; Bradley DT; Fagbamigbe AF; Grange Z; Hall ECR; Joy M; Katikireddi SV; Kerr S; Ritchie L; Murphy S; Owen RK; Rudan I; Shah SA; Simpson CR; Torabi F; Tsang RSM; de Lusignan S; Lyons RA; O'Reilly D; Sheikh A
    Lancet; 2022 Oct; 400(10360):1305-1320. PubMed ID: 36244382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.
    Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Meijerink H; Ljung R; Hviid A
    BMJ; 2023 Jul; 382():e075286. PubMed ID: 37491022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
    Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
    Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada.
    Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Fafard J; Gilca R; Talbot D; Ouakki M; Febriani Y; Deceuninck G; De Wals P; De Serres G
    Lancet Healthy Longev; 2023 Aug; 4(8):e409-e420. PubMed ID: 37459879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
    Arbel R; Peretz A; Sergienko R; Friger M; Beckenstein T; Duskin-Bitan H; Yaron S; Hammerman A; Bilenko N; Netzer D
    Lancet Infect Dis; 2023 Aug; 23(8):914-921. PubMed ID: 37062302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
    Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.